CommercialCoverageMedium impact
Tzield® (Teplizumab-Mzwv)
UnitedHealthcare·Endocrinology, Pediatrics, Internal Medicine·Medical Benefit Drug Policy
Effective date
Oct 1, 2026
We identified it
Sep 2, 2026
Summary
UnitedHealthcare Surest has issued a revised medical benefit drug policy for Tzield® (Teplizumab-Mzwv) effective October 1, 2026. The policy document title and metadata are provided, but the actual policy content details (coverage criteria, prior authorization requirements, billing codes, dosing, and medical necessity guidelines) are not included in the source material available for analysis.
Action Required
By September 15, 2026: Billing and clinical teams must obtain and review the complete Tzield® (Teplizumab-Mzwv) policy from the UnitedHealthcare provider portal at https://www.uhcprovider.com/content/dam/provider/docs/public/policies/mpub-archives/surest/surest-medical-policy-update-bulletin-september-2026.pdf. Identify specific prior authorization requirements, covered indications, billing codes (likely HCPCS J-codes for the drug), and any documentation requirements. Update billing system rules, prior authorization workflows, and provider encounter documentation templates accordingly before the October 1, 2026 effective date. Failure to implement required prior authorization or use correct billing codes will result in claim denials.